Sign In

Brad Robling

Vice President Lilly New Ventures / Corporate Business Development at Eli Lilly and Company

Bradley (Brad) Robling serves as the Vice President of Lilly New Ventures / Corporate Business Development at Eli Lilly Corporation, under the direction of the Executive Vice President of Corporate Development.

In his role, Brad oversees and executes Lilly's corporate venture capital investments, forging partnerships, managing fund investments, participating in boards, and strategizing the management of the venture portfolio.

Apart from venture capital investing, Brad has experience in corporate development, leading significant strategic transactions like mergers, acquisitions, divestitures, licensing agreements, and collaborations within the biopharmaceutical space.

With a background touching professional services firms like Ernst and Young, Deloitte Consulting, and leadership roles at startups in Silicon Valley, Brad brings a wealth of financial and business development acumen to his current position.

Brad's educational foundation was laid at Indiana University Bloomington, and he currently serves on the board of Sitryx Therapeutics, a UK-based biopharmaceutical company focused on developing disease-modifying therapeutics in immuno-oncology and immuno-inflammation.

Highlights

Nov 7 · Business Wire
Black Opal Ventures: Women-led VC Fund Investing in Technology ... - Business Wire
Black Opal Ventures: Women-led VC Fund Investing in Technology ... - Business Wire
B
Add to my network

Location

Danville, California, United States